

## **Wakelee, Heather**

### **Institution/Organization**

Stanford University and Stanford Cancer Institute

### **Primary Specialty**

Medical Oncology

### **Annual Disclosures & Policy Agreements**

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

### **COI Policy Review and Compliance**

Understood

### **Disclosure of Potential Conflicts**

Understood

### **COI Disclosure**

Enter disclosures directly into the disclosure form.

### **Disclosures**

AstraZeneca: Participated in advisory board in 2020, Local PI of clinical trial

Janssen: Advisory; board

Daiichi Sankyo: Advisory board

Blueprint: Advisory board

Mirati: Advisory role

Fishawack: Facilitate LTD Ongoing series of lectures

Medscape AND Research to Practice AND Curio Science: Multiple CME events

MJH holdings (PER): Multiple CME events/conferences; Participation in multiple CME lecture events and as chair of annual conference

UpToDate: Royalty payments

Axis Medical Education and Nexus Oncology: CME events

ACEA Biosciences: Local PI on trial

Arrys Therapeutics: Local PI of trial

BMS (and former Celgene): Local PI of trial and coordinating PI of IIT for former Celgene

Clovis Oncology: Local PI of trial

Genentech/Roche: Local PI of trial and Steering Committee Member

Merck: Local PI of trial and Steering Committee Member

Novartis: Local PI

Xcovery: Local PI of trial and Steering Committee Member

Seagen: Local PI of trial

Helsinn: Local PI of trial

Nexus Oncology: Gave CME lecture

**COI Disclosure Certification**

Disclosed

**Confidentiality Agreement**

Agree

**Standards of Conduct Agreement**

Agree

**IASLC's Tax-Exempt Status**

Agree

**COI Follow-Up**

**Disclose any clinical trials you are conducting for institution fees.**

I am conducting multiple ongoing studies (of note some of the conflicts disclosed above are for trials which are no longer open so not all listed conflicts on first page are reflected here):

Genentech/Roche - IMpower010

Helsinn - next generation selective RET inhibitor trial Merck- 671 neo-adjuvant pembro

Seagen - Institutional PI for phase I trial of novel ADC Xcovery - compassionate use study of ensartinib  
Also institutional PI for several ECOG-ACRIN trials

**Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.**

Executive Committee of ECOG-ACRIN Conference Chair PER ILCC annual meeting

**Have you received any personal fees from any outside accreditation entities such as CME companies?**

Yes, disclosed on first page.

**Are you conducting clinical trials with any oncology equipment companies?**

No

## **Mitsudomi, Tetsuya**

### **Institution/Organization**

Kindai University Faculty of Medicine

### **Primary Specialty**

Thoracic Surgery

### **Annual Disclosures & Policy Agreements**

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

### **COI Policy Review and Compliance**

Understood

### **Disclosure of Potential Conflicts**

Understood

### **COI Disclosure**

#### **Disclosures**

AstraZeneca: advisory role, speaker fee

MSD: advisor role, speaker fee

Novartis: advisor role, speaker fee

Bristol Myers Squibb: advisor role, speaker fee

Ono: advisor role, speaker fee

Pfizer: advisor role, speaker fee

Boehringer Ingelheim: advisor role, speaker fee

Eli-Lilly: Speaker

Chugai: advisor role, speaker fee

Janssen:

Amgen: advisor role

Daiichi-Sankyo: advisory role

Taiho: advisor, speaker

INVITAE: speaker role

Bayer: speaker

Thermofisher: speaker advisor

**COI Disclosure Certification**

Disclosed

**Confidentiality Agreement**

Agree

**Standards of Conduct Agreement**

Agree

**IASLC's Tax-Exempt Status**

Agree

**COI Follow-Up**

**Disclose any clinical trials you are conducting for institution fees.**

Agean CheckMate 816 Keynote-091 BR.31

**Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.**

President, The Japan Lung Cancer Society 2014-2018

Board of Director, Japanese Society of Medical Oncology 2013-2019 Coard of Director, Japanese Association for Chest Surgery 2013-2019

**Have you received any personal fees from any outside accreditation entities such as CME companies?**

No

**Are you conducting clinical trials with any oncology equipment companies?**

No

## **Van Schil, Paul**

### **Institution/Organization**

Antwerp University Hospital

### **Primary Specialty**

Thoracic Surgery

### **Annual Disclosures & Policy Agreements**

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

### **COI Policy Review and Compliance**

Understood

### **Disclosure of Potential Conflicts**

Understood

### **COI Disclosure**

#### **Disclosures**

AstraZeneca: External expert

MSD: External expert

BACTS (Belgian Association for Cardio-Thoracic Surgery): Treasurer - board member

Roche: external expert

#### **COI Disclosure Certification**

Disclosed

#### **Confidentiality Agreement**

Agree

#### **Standards of Conduct Agreement**

Agree

#### **IASLC's Tax-Exempt Status**

Agree

### **COI Follow-Up**

**Disclose any clinical trials you are conducting for institution fees.**

none

**Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.**

Treasurer and board member BACTS (Belgian Association for Cardiothoracic Surgery) 2019-2023

**Have you received any personal fees from any outside accreditation entities such as CME companies?**

no

**Are you conducting clinical trials with any oncology equipment companies?**

No

## **Bezjak, Andrea**

### **Institution/Organization**

Princess Margaret Cancer Center

### **Primary Specialty**

Radiation Oncology

### **Annual Disclosures & Policy Agreements**

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

### **COI Policy Review and Compliance**

Understood

### **Disclosure of Potential Conflicts**

Understood

### **COI Disclosure**

Enter disclosures directly into the disclosure form.

### **Disclosures**

Princess Margaret Cancer Center: Employment

University of Toronto: academic appointment

Astra Zeneca: Advisory Board

### **COI Disclosure Certification**

Disclosed

### **Confidentiality Agreement**

Agree

### **Standards of Conduct Agreement**

Agree

### **IASLC's Tax-Exempt Status**

Agree

### **COI Follow-Up**

**Disclose any clinical trials you are conducting for institution fees.**



Pacific-4 Phase III trial of SBRT +/- Durvalumab - funded by Astra Zeneca, my role is coinvestigator, fees paid to institution

**Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.**

Secretary of the Board of CROF (Canadian Radiation Oncology Foundation)

**Have you received any personal fees from any outside accreditation entities such as CME companies?**

No

**Are you conducting clinical trials with any oncology equipment companies?**

No

## **Thunnissen, Erik**

### **Institution/Organization**

Amsterdam University Medical Center

### **Primary Specialty**

Pathology

### **Annual Disclosures & Policy Agreements**

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

### **COI Policy Review and Compliance**

Understood

### **Disclosure of Potential Conflicts**

Understood

### **COI Disclosure**

I have no potential Conflicts of Interest to disclose.

### **COI Disclosure Certification**

Disclosed

### **Confidentiality Agreement**

Agree

### **Standards of Conduct Agreement**

Agree

### **IASLC's Tax-Exempt Status**

Agree

### **Disclose any clinical trials you are conducting for institution fees.**

n.a.

### **Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.**

n.a.

### **Have you received any personal fees from any outside accreditation entities such as CME companies?**

n.a.

**Are you conducting clinical trials with any oncology equipment companies?**

No

## **Kelly, Karen**

### **Institution/Organization**

International Association for the Study of Lung Cancer

### **Primary Specialty**

Medical Oncology

### **Annual Disclosures & Policy Agreements**

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

### **COI Policy Review and Compliance**

Understood

### **Disclosure of Potential Conflicts**

Understood

### **COI Disclosure**

#### **Disclosures**

UpToDate: Write chapters; Personal

Genentech: Advisory boards - 3 and local PI of two clinical trials Institutional, Personal

Sanofi: Advisory Board, Personal

EMD Serono: advisory board and local PI of two trials Institutional, Personal

AstraZeneca: advisory board – 3; Personal

Takeda: advisory board; Personal

Novartis: clinical trial steering committee meeting and local PI Institutional, Personal

Eisai: advisory board; Personal

Amgen: advisory board and local PI of a clinical trial; Institutional, Personal

Genmab: advisory board; Personal

ABBVIE: Advisory board and local PI of two clinical trials; Institutional, Personal

Jounce Therapeutics: Local PI of a clinical trial; Institutional

BMS: Local PI of a clinical trial; Institutional

Tizona Therapeutics: Local PI of two clinical trials; Institutional

Astellas Pharma; Local PI of a clinical trial; Institutional

Janssen: advisory board; Personal

**COI Disclosure Certification**

Disclosed

**Confidentiality Agreement**

Agreed

**Standards of Conduct Agreement**

Agreed

**IASLC's Tax-Exempt Status**

Agreed

**COI Follow-Up**

**Disclose any clinical trials you are conducting for institution fees.**

Please see previous page

**Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.**

On the parent committee for DOD Lung Cancer grants

**Have you received any personal fees from any outside accreditation entities such as CME companies?**

I have received honorarium for speaking from MJH life sciences and the Medical Educator Consortium

**Are you conducting clinical trials with any oncology equipment companies?**

No

## **Aerts, Joachim**

### **Institution/Organization**

Erasmus University Medical Center

### **Primary Specialty**

Pulmonary Medicine

### **Annual Disclosures & Policy Agreements**

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

### **COI Policy Review and Compliance**

Agree

### **Disclosure of Potential Conflicts**

Read and understood

### **COI Disclosure**

#### **Disclosures**

Amphera: advisor and stock owner and performance of clinical trials

Eli-Lilly: speaker and research funding

MSD: speaker and advisor

AstraZeneca: advisor

BIOCAD: speaker and DSMB member

BMS: advisory board

Genmab: steering co member

### **COI Disclosure Certification**

Disclosed

### **Confidentiality Agreement**

Agree

### **Standards of Conduct Agreement**

Understand and agree

### **IASLC's Tax-Exempt Status**

Agree

### **COI Follow-Up**

#### **Disclose any clinical trials you are conducting for institution fees.**

- SPI-POZ studie: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1).
- ETOP CHESS : A multicentre single arm phase II trial assessing the efficacy of radical immunotherapy and chemotherapy, stereotactic radiotherapy and surgery in patients with synchronous oligo-metastatic NSCLC.
- LIBRETTO-431 (Lilly): A multicenter, randomized, open-label, phase 3 trial comparing LOXO-292 to platinum-based and pemetrexed therapy with or without pembrolizumab as initial treatment of advanced or metastatic RET fusion- positive non-small cell lung cancer
- Sapphire (MIRATI therapeutic): A Randomized Phase 3 Study of Sitravatinib Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum–Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy
- Daiichi Sankyo Tropion lung01: Phase 3 randomized study of DS-1062A versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer without actionable genomic alterations, protocol number DS1062- A-U301
- Daiichi Sankyo Tropion 05: Phase 2, multicenter, randomized, open-label study of DS-1062a in advanced or metastatic non-small cell lung cancer with actionable genomic alterations and previously treated with kinase inhibitor therapy and platinum-based chemotherapy with or without immunotherapy DS1062-A-U202
- Daiichi Sankyo Destiny lung02: A phase 2, multicenter, randomized study of trastuzumab deruxtecan in subjects with HER2-mutated metastatic non-small cell lung cancer (NSCLC) DS8201-A-U206
- EORTC 1825 (Alkaline): Activity of Lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with 2nd generation ALK inhibitor
- EORTC 1525: Single-arm, , phase II study of nivolumab in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy – (NIVOTHYM)
- Roche MO41552 Entrectinib: Randomized, open label, multicenter, phase III study of entrectinib versus crizotinib in patients who have nonsmall cell lung cancer harboring ros1 gene rearrangements with and without central nervous system metastases.
- Mirati Krystal program: 849-007: A phase 2 trial of MRTX849 in combination with pembrolizumab in patients with advanced non-small cell lung cancer with KRAS G12C mutation
- Start TKI : ProSpecTive sAmpling in dRiver muTation pulmonary oncology patients one Tyrosine Kinase Inhibitors (START-TKI).

- Satin studie: Safety of TKI concurrent with cranial radiotherapy in NSCLC patients; the SATIN platform trial
- Orchard studie (AstraZeneca): Biomarker-Directed, Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease Has Progressed on First-Line Therapy with Osimertinib (Tagrisso) to Assess the Safety, Tolerability, and Efficacy of Different Treatment Options for Patients Following Epidermal Growth Factor Tyrosine Kinase Inhibitor (ORCHARD).
- ImmunoSABR: Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer.
- NutriCim: The effects of an oncology tailored nutritional intervention on the bioavailability and immune-activity of PD- 1 immune checkpoint inhibitors in patients with lung cancer
- TEIPP studie: T-cell Epitopes associated with Impaired Peptide Processing (TEIPP)-targeting immunotherapy in patients with relapsed advanced non small cell lung cancer (NSCLC)
- ENSURE: dENDritic cell therapy combined with SURgEry in mesothelioma
- Achilles studie: A randomized phase II study comparing atezolizumab after concurrent chemo-radiotherapy with chemo-radiotherapy alone in limited disease small-cell lung cancer
- Checkmate 77T: A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIb Non-small Cell Lung Cancer
- Amgen 20190009: A phase 3 multicenter, randomized, open label, active-controlled, study of AMG 510 versus docetaxel for the treatment of previously treated locally advanced and unresectable or metastatic NSCLC subjects with mutated KRAS p. G12C
- Skyscraper: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab plus carboplatin and etoposide with or without tiragolumab (anti-tigit antibody) in patients with untreated extensive-stage small cell lung cancer
- Denim: A Randomized, Open-Label Phase II/III Study with Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects with Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy
- Caspian: A phase III, randomized, multicenter, open-label, comparative study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy for the first-line treatment in patients with extensive disease (stage IV) small-cell lung cancer
- BMS 6 (CA209817): A Phase IIIb/IV safety trial of flat dose nivolumab in combination with ipilimumab in participants with advanced malignancies
- BMS 7 (CA209743): a phase III, randomized, open label trial of Nivolumab in combination with ipilimumab versus pemetrexed with cisplatin or carboplatin as first line therapy in unresectable pleural mesothelioma



- NVALT 24: a phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer
- Afacet: Phase II study of Afatinib in combination with Cetuximab in EGFR exon 20 insertion positive non-small-cell lung cancer
- Prima: Prospective tumor sampling in oncology patients with solid tumors treated with Immune Modulating Agents
- Ultima: Prospective sampling in intravenously treated oncology patients: Immune Modulating Agents
- Lorlatinib: Lorlatinib neurocognitive adverse events: how to improve patient care

**Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.**

none

**Have you received any personal fees from any outside accreditation entities such as CME companies?**

none

**Are you conducting clinical trials with any oncology equipment companies?**

No

## **Gray, Jhanelle**

### **Institution/Organization**

Moffitt Cancer Center

### **Primary Specialty**

Medical Oncology

### **Annual Disclosures & Policy Agreements**

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

### **COI Policy Review and Compliance**

Understood

### **Disclosure of Potential Conflicts**

Understood

### **COI Disclosure**

#### **Disclosures**

AbbVie: Consulting / Advisory Role

American Society of Clinical Oncology: Consulting / Advisory Role

AstraZeneca: Consulting / Advisory Role

Axiom HC Strategies: Consulting / Advisory Role

Blueprint Medicines: Consulting / Advisory Role

Bristol-Myers Squibb: Consulting / Advisory Role

Celgene Corp: Consulting / Advisory Role

Daiichi Sankyo, Inc: Consulting / Advisory Role

Eli Lilly & Company: Consulting / Advisory Role

EMD Serono: Consulting / Advisory Role

Genentech: Consulting / Advisory Role

Inivata: Consulting / Advisory Role

Janssen Scientific Affairs, LLC Consulting: / Advisory Role

Jazz Pharmaceuticals: Consulting / Advisory Role

Loxo Oncology, Inc: Consulting / Advisory Role

Merck & Co., Inc: Consulting / Advisory Role

Novartis Pharmaceuticals: Consulting / Advisory Role

OncoCyte Biotechnology Company: Consulting / Advisory Role

Sanofi Pharmaceuticals: Consulting / Advisory Role

Takeda Pharmaceuticals: Consulting / Advisory

Triptych Health Partners: Consulting / Advisory Role

**COI Disclosure Certification**

Disclosed

**Confidentiality Agreement**

Agree

**Standards of Conduct Agreement**

Agree

**IASLC's Tax-Exempt Status**

Agree

**COI Follow-Up**

**Disclose any clinical trials you are conducting for institution fees.**

Alliance For Clinical Trials in Oncology - SWOG Array BioPharma Inc

AstraZeneca Boehringer Ingelheim Bristol-Myers Squibb

Calithera Biosciences, Inc Daiichi Pharma

ECOG-ACRIN

Genentech

G1 Therapeutics

James & Esther King Biomedical Research Ludwig Institute of Cancer Research Merck & Co., Inc

Novartis Pfizer

**Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.**

ASCO Education Committee Chair - 2021/2022

IASLC Membership Committee Chair - 2018 to Present

WCLC 2021 Meeting, Locally Advanced NSCLC Education Session and Program Track Chair - 2021 to Present  
SWOG Lung-MAP Sub-Study Committee (S1900B / LOXO) Chair - 2019 to Present

SWOB Lung Committee - elected Chair as of 4/1/2022

**Have you received any personal fees from any outside accreditation entities such as CME companies?**

No

**Are you conducting clinical trials with any oncology equipment companies?**

No

## **Herbst, Roy**

### **Institution/Organization**

Yale Cancer Center

### **Primary Specialty**

Medical Oncology

### **Annual Disclosures & Policy Agreements**

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

### **COI Policy Review and Compliance**

Understood

### **Disclosure of Potential Conflicts**

Understood

### **COI Disclosure**

#### **Disclosures**

Immunocore: Interested Person/ Financial; Board Member (non-executive/ independent)

Junshi Pharmaceuticals: Interested Person/ Financial; Board Member (non-executive/ independent)

AstraZeneca: Financial

Bolt Biotherapeutics: Financial

Bristol-Myers Squibb: Financial

Candel Therapeutics, Inc.: Financial

Checkpoint Therapeutics: Financial

DynamiCure Biotechnology, LLC: Financial

eFFECTOR Therapeutics, Inc.: Financial

Eli Lilly and Company: Financial

EMD Serono: Financial

Genentech: Financial

Gilead: Financial

HiberCell, Inc.: Financial

I-Mab Biopharma: Financial

Immune-Onc Therapeutics, Inc.: Financial

Janssen: Financial

Johnson and Johnson: Financial

Loxo Oncology: Financial

Merck and Company: Financial

Mirati Therapeutics: Financial

NextCure: Other Potential Conflict of Interest; Trail Support

Novartis: Financial

Ocean Biomedical, Inc.: Financial

Oncocyte Corp: Financial

Oncternal Therapeutics: Financial

Pfizer: Financial

Regeneron Pharmaceuticals: Financial

Ribbon Therapeutics: Financial

Roche: Financial

Sanofi: Financial

Xencor, Inc: Financial

**COI Disclosure Certification**

Disclosed

**Confidentiality Agreement**

Agreed

**Standards of Conduct Agreement**

Agreed

**IASLC's Tax-Exempt Status**

Agreed

**COI Follow-Up**

**Disclose any clinical trials you are conducting for institution fees.**

A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006), Merck

AZD9291 Versus Placebo in Patients With Stage IB-IIIa Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA), AstraZeneca

A Phase I-2 Trial of NC318 combined with Pembrolizumab in refractory Non-small Cell Lung Cancer: Yale Cancer Center IIT

**Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.**

American Association for Cancer Research Society for Immunotherapy of Cancer Southwest Oncology Group

**Have you received any personal fees from any outside accreditation entities such as CME companies?**

Answers in CME (AICME) Aptitude Health

AXIS Medical Education BioMedical Learning Institute Creative Educational Concepts Clinical Care Options

OnLive

OE Oncology Education MJH Life Sciences PeerView

PeerVoice

Physicians' Education Resource (PER)

PlatformQ pRIMEOncology Projects In Knowledge Research To Practice RMEI Medical Education Vindico CME

**Are you conducting clinical trials with any oncology equipment companies?**

No

## **Kim, Young Tae**

### **Institution/Organization**

Seoul National University

### **Primary Specialty**

Thoracic Surgery

### **Annual Disclosures & Policy Agreements**

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

### **COI Policy Review and Compliance**

Understood

### **Disclosure of Potential Conflicts**

Understood

### **COI Disclosure**

#### **Disclosures**

AstraZeneca: Speaker

Johnson and Johnson: Consultant, Speaker

#### **COI Disclosure Certification**

Disclosed

#### **Confidentiality Agreement**

Agree

#### **Standards of Conduct Agreement**

Agree

#### **IASLC's Tax-Exempt Status**

Agree

### **COI Follow-Up**

**Disclose any clinical trials you are conducting for institution fees.**

None



**Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.**

Board for Korean Cancer Association

**Have you received any personal fees from any outside accreditation entities such as CME companies?**

None

**Are you conducting clinical trials with any oncology equipment companies?**

No

## **Moreira Ferreira, Carlos Gil**

### **Institution/Organization**

Instituto Oncoclinicas

### **Primary Specialty**

### **Annual Disclosures & Policy Agreements**

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

### **COI Policy Review and Compliance**

Understood

### **Disclosure of Potential Conflicts**

Understood

### **COI Disclosure**

I have no potential Conflicts of Interest to disclose.

### **COI Disclosure Certification**

Disclosed

### **Confidentiality Agreement**

Agree

### **Standards of Conduct Agreement**

Agree

### **IASLC's Tax-Exempt Status**

Agree

### **COI Follow-Up**

**Disclose any clinical trials you are conducting for institution fees.**

No.

**Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.**

Board Member Americas Health Foundation (AHF). CMO of Oncoclinicas Group and shareholder.

**Have you received any personal fees from any outside accreditation entities such as CME companies?**

No.

**Are you conducting clinical trials with any oncology equipment companies?**

No

## **Quist, Morten**

### **Institution/Organization**

University hospital Copenhagen

### **Primary Specialty**

Resp Therapy/Physiotherapy

### **Annual Disclosures & Policy Agreements**

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

#### **COI Policy Review and Compliance**

Understood

#### **Disclosure of Potential Conflicts**

Understood

#### **COI Disclosure**

I have no potential Conflicts of Interest to disclose.

#### **COI Disclosure Certification**

Disclosed

#### **Confidentiality Agreement**

Agree

#### **Standards of Conduct Agreement**

Agree

#### **IASLC's Tax-Exempt Status**

Agree

#### **COI Follow-Up**

**Disclose any clinical trials you are conducting for institution fees.**

none

**Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.**

Board of the danisk lung cancer group

**Have you received any personal fees from any outside accreditation entities such as CME companies?**

no

**Are you conducting clinical trials with any oncology equipment companies?**

No

## **Sequist, Lecia**

### **Institution/Organization**

Massachusetts General Hospital

### **Primary Specialty**

Medical Oncology

### **Annual Disclosures & Policy Agreements**

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

### **COI Policy Review and Compliance**

Understood

### **Disclosure of Potential Conflicts**

Understood

### **COI Disclosure**

#### **Disclosures**

AstraZeneca: Consulting

AstraZeneca: Clinical trial funding; Up to 2021

Genentech: Data Safety Monitoring Committee; Up to 2021

Massachusetts General Hospital: Primary site of Employment

American Lung Association: Educational lecture; 2020

American Society of Clinical Oncology: Educational lecture; 2019

BioAscend: Educational lecture; 2020

Clinical Care Options: Educational lecture; 2021

Creative Educational Concepts: Lecture and course director Personal; Up to 2021

Dana Farber Cancer Institute: Lecture; 2019

E-vate LTD: Consulting; 2020

Flagship Labs 67, Inc: consulting; 2020

Harvard University: Educational lecture; 2019

Inception Digital: Educational lecture; 2019

Intellisphere, LLC: Educational lecture; 2019

Janssen: Educational lecture; 2020

National Cancer Institute: Steering Committee; Up to 2021

LUNGeivity: Scientific Advisory Board; Up to 2021

MJH Healthcare Holdings, LLC: Educational Lecture; Up to 2021

Nexus Global Group Science, LLC: Consulting; 2019

Ohio State University: Educational Lecture; 2021

Peer View, LLC: Educational Lecture; 2021

PlatformQ Health, Inc: Consulting; 2019

Prime Oncology: Educational lecture; 2019

PSL Group Americas: Educational Lecture; 2019

Research To Practice: Educational Lecture; Up to 2021

Touch Medical Media: Educational Lecture; 2021

Triptych Health Partners: Educational Lecture; 2021

UpToDate: Writing; Up to 2021

WebMD: Educational lectures and course director; up to 2021

Novartis: Clinical Trial

Delfi: Clinical Trial

**COI Disclosure Certification**

Disclosed

**Confidentiality Agreement**

Agreed

**Standards of Conduct Agreement**

Agreed

**IASLC's Tax-Exempt Status**

Agreed

**COI Follow-Up**

**Disclose any clinical trials you are conducting for institution fees.**

I serve as the PI for the following clinical trials at my institution (2019-2021):

1. A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients with EGFRm, Metastatic NSCLC who have Progressed Extracranially following First-Line Osimertinib Therapy (COMPEL), funded by AstraZeneca
2. A Multi-center, AZD9291 Expanded Access Program for the Treatment of Patients with Advanced/Metastatic EGFR T790M Mutation-Positive Non-small Cell Lung Cancer (NSCLC) Who Have Received Prior EGFR TKI Therapy, funded by AstraZeneca
3. A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a standard of care epidermal growth factor receptor Tyrosine Kinase Inhibitor as First-Line treatment in patients with epidermal growth factor receptor mutation positive, locally advanced or metastatic non-small cell lung cancer, funded by AstraZeneca
4. A Multi-arm, Phase Ib, Open-Label, Multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9291 in combination with ascending doses of novel therapeutics in patients with EGFRm+ advanced NSCLC who has progressed following therapy with an EGFR TKI (TATTON), funded by AstraZeneca
5. A Phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR mutated non-small cell lung cancer, funded by Novartis

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

1. LUNGeivity, Scientific Advisory Board
2. American Lung Association, Massachusetts Leadership Board, Scientific and Medical Editorial Review Panel, and Chair of the local Lung Force Expo meeting
3. Member, Board of Directors, Upstage Lung Cancer Foundation
4. Oregon Health Sciences University Cancer Early Detection and Advanced Research Center, External Advisory Committee
5. Leader, Cancer Risk, Prevention, and Early Detection Program, Dana-Farber Harvard Cancer Center
6. The Fleischner Study, Member-Elect



7. NCI Thoracic Malignancy Steering Committee, member
8. American Society of Clinical Oncology: Thoracic Cancer Guideline Advisory Group, Cancer Prevention Committee, and Virtual Mentorship Program
9. The Oncology Journal: Lung cancer section editor
10. Eastern Cooperative Oncology Group: lung cancer core committee
11. American Association for Cancer Research: Lung Cancer Research Grants Scientific Review Committee, Chair, Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research Selection Committee
12. European Society of Medical Oncology, Contributor, EGFR mutation positive lung cancer consensus guidelines and member, Scientific Committee
13. American Cancer Society, PI for a grant which gives out institutional research grants
14. Zhu Family Center for Global Cancer Prevention, Harvard T.H. Chan School of Public Health, member

**Have you received any personal fees from any outside accreditation entities such as CME companies?**

Yes, they are all disclosed above

**Are you conducting clinical trials with any oncology equipment companies?**

Yes

**Please disclose the names of any oncology equipment companies for which you are conducting any clinical trials.**

Will be opening a clinical trial soon with a blood test made by Delfi Diagnostics

## **Tsao, Ming S.**

### **Institution/Organization**

University Health Network, Princess Margaret Cancer Centre

### **Primary Specialty**

Pathology

### **Annual Disclosures & Policy Agreements**

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

### **COI Policy Review and Compliance**

Understood

### **Disclosure of Potential Conflicts**

Understood

### **COI Disclosure**

#### **Disclosures**

University Health Network, Princess Margaret Cancer Centre: Senior Scientist, Consultant Pathologist

Bayer Inc.: Research grant; multi-institutional study to standardize NTRK testing in Canada

Sanofi: Research grant (pending) to study CEACAM5 expression in lung cancer

AstraZeneca: Honoraria for adhoc consultancy advisory board meetings

Bayer: Honoraria for consultancy advisory board meeting

Amgen: Honorarium for consultancy advisory board meeting

Daichii-Sankyo: Honorarium for consultancy advisory board meeting

Abbvie: Honorarium for consultancy advisory board meeting

Diaceutics: Honorarium for consultancy advisory board

Eli Lilly: Honorarium for consultancy advisory board meeting

Nucleix: Advisor

Pertuba: Scientific Advisory Board member

Merck: Honorarium for consultancy advisory board meeting

BMS: Honorarium for consultancy advisory board meeting

Eli Lilly: Unrestricted grant for fellowship training

**COI Disclosure Certification**

Disclosed

**Confidentiality Agreement**

Agree

**Standards of Conduct Agreement**

Agree

**IASLC's Tax-Exempt Status**

Agree

**COI Follow-Up**

**Disclose any clinical trials you are conducting for institution fees.**

No

**Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.**

Member of External Scientific Advisory Board:

1. University of Texas Southwestern Lung SPORE grant
2. Mount Sinai Hospital (New York) Thoracic Oncology Program
3. Marseille Immunopole "PIONeer" Project

**Have you received any personal fees from any outside accreditation entities such as CME companies?**

Medscape for satellite symposium speaker (ESMO 2019)

**Are you conducting clinical trials with any oncology equipment companies?**

No

## **Ugalde Figueroa, Paula**

### **Institution/Organization**

Brigham and Women's Hospital

### **Primary Specialty**

Thoracic Surgery

### **Annual Disclosures & Policy Agreements**

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

### **COI Policy Review and Compliance**

Understood

### **Disclosure of Potential Conflicts**

Understood

### **COI Disclosure**

I have no potential Conflicts of Interest to disclose.

### **COI Disclosure Certification**

Disclosed

### **Confidentiality Agreement**

Agree

### **Standards of Conduct Agreement**

Agree

### **IASLC's Tax-Exempt Status**

Agree

### **COI Follow-Up**

**Disclose any clinical trials you are conducting for institution fees.**

None

**Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.**

None

**Have you received any personal fees from any outside accreditation entities such as CME companies?**

No

**Are you conducting clinical trials with any oncology equipment companies?**

No

## **Zhou, Caicun**

### **Institution/Organization**

Tongji University Shanghai Pulmonary Hospital

### **Primary Specialty**

Medical Oncology

### **Annual Disclosures & Policy Agreements**

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

### **COI Policy Review and Compliance**

Understood

### **Disclosure of Potential Conflicts**

Understood

### **COI Disclosure**

#### **Disclosures**

Lily China: honoraria as a speaker

Sanofi: honoraria as a speaker

BI: honoraria as a speaker

Roche China: honoraria as a speaker

MSD: honoraria as a speaker

Qilu: honoraria as a speaker

Hengrui: honoraria as a speaker and Advisor

Innovent Biologics: honoraria as a speaker and

C-Stone: honoraria as a speaker

LUYE Pharma: honoraria as a speaker

TopAlliance Biosciences Inc: honoraria as a speaker and Advisor

Amoy Diagnostics: honoraria as a speaker

### **COI Disclosure Certification**

Disclosed

**Confidentiality Agreement**

Agreed

**Standards of Conduct Agreement**

Agreed

**IASLC's Tax-Exempt Status**

Agreed

**COI Follow-Up**

**Disclose any clinical trials you are conducting for institution fees.**

C-Stone Hengrui Beigene

Innovent Biologics

**Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.**

Chairman of Non-small Cell lung Cancer Professional Committee of Chinese Society of Clinical Oncology  
Chairman Elect of Anti-tumor Drug Research Professional Committee of Chinese Anti-cancer Association

**Have you received any personal fees from any outside accreditation entities such as CME companies?**

No

**Are you conducting clinical trials with any oncology equipment companies?**

No